One or more of the required application components couldn’t be loaded. Please, refresh the page.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
9:17 AM
Theme 		Help

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SBFM

Sunshine Biopharma Inc

Last Close
Apr 04 • 04:00PM ET
1.57
Dollar change
-0.27
Percentage change
-14.67%
Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD
SBFM - Stock Price Chart
Peers: REGN GILD VRTX AMGN BIIB ALNY INCY EXEL NBIX MDGL
Scroll to Statements
Index- P/E- EPS (ttm)-51.76 Insider Own0.08% Shs Outstand2.71M Perf Week-21.50%
Market Cap4.25M Forward P/E2.12 EPS next Y0.74 Insider Trans0.00% Shs Float2.71M Perf Month-32.91%
Income-5.13M PEG- EPS next Q0.01 Inst Own6.08% Short Float4.17% Perf Quarter-49.84%
Sales34.87M P/S0.12 EPS this Y98.92% Inst Trans94.37% Short Ratio0.09 Perf Half Y-46.42%
Book/sh9.10 P/B0.17 EPS next Y117.96% ROA-17.73% Short Interest0.11M Perf Year-99.28%
Cash/sh3.58 P/C0.44 EPS next 5Y- ROE-22.97% 52W Range1.75 - 248.00 Perf YTD-47.67%
Dividend Est.- P/FCF- EPS past 5Y82.07% ROI-21.18% 52W High-99.37% Beta1.21
Dividend TTM- Quick Ratio2.33 Sales past 5Y551.91% Gross Margin29.95% 52W Low-10.09% ATR (14)0.31
Dividend Ex-Date- Current Ratio4.11 EPS Y/Y TTM86.42% Oper. Margin-16.52% RSI (14)32.02 Volatility30.85% 13.44%
Employees52 Debt/Eq0.04 Sales Y/Y TTM44.75% Profit Margin-14.72% Recom1.00 Target Price15.00
Option/ShortNo / Yes LT Debt/Eq0.03 EPS Q/Q99.20% Payout- Rel Volume0.55 Prev Close1.84
Sales Surprise-28.52% EPS Surprise99.82% Sales Q/Q24.93% EarningsNov 06 BMO Avg Volume1.21M Price1.57
SMA20-23.99% SMA50-32.91% SMA200-53.56% Trades Volume665,292 Change-14.67%
Apr-03-25 10:50AM
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
(ACCESSWIRE) -18.22%
Apr-02-25 01:20PM
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
(ACCESSWIRE) +8.17%
08:00AM
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
(ACCESSWIRE)
Apr-01-25 05:09PM
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
(ACCESSWIRE) +8.90%
Mar-25-25 09:06AM
Sunshine Biopharma signs agreement for rights to market two generic antibiotics
(TipRanks)
09:00AM Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Mar-10-25 09:00AM
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
(ACCESS Newswire) -5.02%
Jan-21-25 08:00AM
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
(ACCESSWIRE)
Jan-15-25 08:00AM
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
(ACCESSWIRE)
Dec-09-24 07:30AM
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
(ACCESSWIRE) -10.78%
Dec-04-24 04:05PM
Sunshine Biopharma Launches a New Generic Prescription Drug
(ACCESSWIRE) +6.45% +8.75%
Dec-02-24 08:00AM
Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma
(ACCESSWIRE) +8.39%
Nov-22-24 08:00AM
Sunshine Biopharma Launches a New Generic Prescription Drug
(ACCESSWIRE) +11.32%
Nov-06-24 08:00AM
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
(ACCESSWIRE) -6.29%
Sep-26-24 08:00AM
Sunshine Biopharma Launches Two New Generic Prescription Drugs
(ACCESSWIRE) +6.97%
Sep-04-24 09:15AM
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
(GlobeNewswire)
08:30AM Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
08:30AM
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
(GlobeNewswire)
08:00AM
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
(ACCESSWIRE)
Aug-26-24 08:00AM
Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
(ACCESSWIRE)
Aug-19-24 08:00AM
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
(ACCESSWIRE) +5.82%
Aug-16-24 10:53PM
SBFM Stock Earnings: Sunshine Biopharma Misses EPS, Beats Revenue for Q2 2024
(InvestorPlace) -9.60%
Aug-06-24 08:00AM
Sunshine Biopharma Announces Reverse Stock Split
(ACCESSWIRE) -22.84%
Jun-28-24 06:00AM
7 F-Rated Growth Stocks to Avoid Right Now: June 2024
(InvestorPlace) -5.09%
Jun-20-24 02:51PM
3 Penny Stocks Ready to Explode Into Dollar Signs by 2028
(InvestorPlace) -11.72%
May-21-24 08:00AM
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
(ACCESSWIRE) -17.80%
May-20-24 09:54PM
SBFM Stock Earnings: Sunshine Biopharma Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace) +5.38%
May-16-24 06:15AM
3 Meme Stocks to Sell That Even Roaring Kitty Can't Save
(InvestorPlace)
Apr-19-24 08:00AM
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
(ACCESSWIRE) -46.84%
Apr-12-24 09:00AM
Sunshine Biopharma Announces Reverse Stock Split
(ACCESSWIRE) -8.04%
Apr-08-24 01:53PM
SBFM Stock Earnings: Sunshine Biopharma Misses EPS, Beats Revenue for Q4 2023
(InvestorPlace) -5.10%
Apr-01-24 08:00AM
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
(ACCESSWIRE) +76.03%
09:18AM Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
Mar-04-24 09:18AM
Why Is Sunshine Biopharma (SBFM) Stock Down 17% Today?
(InvestorPlace) -18.95%
Feb-15-24 09:15AM
Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering
(ACCESSWIRE) +6.01%
Feb-13-24 09:00AM
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
(ACCESSWIRE) -63.83%
Dec-04-23 08:30AM
Sunshine Biopharma Moves Principal Office to New York City
(GlobeNewswire) -7.59%
Nov-13-23 08:30AM
Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition
(ACCESSWIRE) -12.08%
Sep-21-23 09:05PM
Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance
(ACCESSWIRE) -9.68%
Aug-11-23 08:30AM
Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%
(GlobeNewswire)
May-16-23 02:15PM
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)
(ACCESSWIRE) -9.52%
09:58AM
Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market
(GlobeNewswire)
May-12-23 08:00AM
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market
(GlobeNewswire) -18.77%
May-11-23 09:00AM
Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%
(GlobeNewswire) +69.81%
Apr-05-23 08:00AM
Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update
(GlobeNewswire) +8.92%
Feb-28-23 07:30AM
Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment
(GlobeNewswire)
Feb-10-23 07:35AM
Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound
(GlobeNewswire) +8.10%
Jan-19-23 07:30AM
Sunshine Biopharma Announces Share Repurchase Program
(GlobeNewswire) -8.50%
Dec-27-22 08:00AM
Insider Buying: Sunshine Biopharma Inc. (NASDAQ: SBFM) Chief Financial Officer Purchases Shares
(News Direct)
Dec-20-22 08:00AM
Sunshine Biopharmas Annual Letter to Shareholders
(GlobeNewswire)
Nov-23-22 11:20AM
NASDAQ: SBFM Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project!
(News Direct)
Nov-16-22 10:12AM
Sunshine Biopharma Collaborates For Its Lead mRNA-Based Cancer Program
(Benzinga)
08:00AM
Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project
(GlobeNewswire)
Nov-13-22 07:52AM
Sunshine Biopharma Third Quarter 2022 Earnings: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)
(Simply Wall St.)
Nov-07-22 09:28AM
What Does Sunshine Biopharmas Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?
(News Direct) -11.93%
Oct-20-22 08:00AM
Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue
(GlobeNewswire)
07:32AM
EXCLUSIVE: Sunshine Biopharma Acquires Canadian Generic Player For $22M
(Benzinga)
Aug-08-22 08:15AM
We're Hopeful That Sunshine Biopharma (NASDAQ:SBFM) Will Use Its Cash Wisely
(Simply Wall St.)
Aug-04-22 08:00AM
Sunshine Biopharma Files Its Second Quarter Report With the SEC
(GlobeNewswire)
Jul-28-22 08:10AM
Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona
(GlobeNewswire) -8.00%
Jun-27-22 05:30AM
SBFM: Working to Change the Cancer Fight
(Zacks Small Cap Research)
Apr-28-22 04:50PM
Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market
(GlobeNewswire) -9.61%
09:20AM
Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)
(ACCESSWIRE)
Apr-26-22 08:13AM
Multiple Promising Treatments Accentuate the Bull Case for Sunshine Biopharma
(InvestorPlace) -17.71%
12:41AM
Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market
(GlobeNewswire)
Apr-25-22 08:00AM
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
(GlobeNewswire) +20.42%
Apr-19-22 06:45PM
Blockbuster Clinical Results Shine a Positive Light on Sunshine Biopharma
(InvestorPlace) +18.50%
02:02PM
EXCLUSIVE: Sunshine Biopharma Looks Ahead In COVID And Cancer Treatments
(Benzinga)
Apr-08-22 09:44AM
BioMed Leaders: Sunshine Biopharma, PharmaDrug, Blue Water Vaccines, and MedAvail; Visionary CEOs Advancing Healthcare, with Vaccines, Cancer Therapeutics, and Affordable Pharmaceuticals
(GlobeNewswire) -37.51%
Apr-05-22 03:45PM
GM and Honda promise affordable EVs, Block shares sink after data breach, SBFM stock booms
(Yahoo Finance Video) +148.23%
01:41PM
Sunshine Biopharma Stock Triples on Positive mRNA Cancer Treatment Results
(InvestorPlace)
08:00AM
Sunshine Biopharmas Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells
(GlobeNewswire)
07:30AM
EXCLUSIVE: Sunshine Biopharma's Newly Designed mRNA Molecules Effective Against Multidrug Resistant Cancer Cells
(Benzinga)
Mar-15-22 09:45AM
Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ: SBFM)
(ACCESSWIRE) +13.15%
Mar-14-22 06:12PM
Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market
(GlobeNewswire)
Mar-10-22 09:17AM
Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market
(GlobeNewswire) -21.58%
Feb-25-22 08:00AM
Sunshine Biopharma Expands Anti-Coronavirus Drug Development Program By Signing A Collaboration Agreement With The University Of Arizona
(GlobeNewswire)
Feb-17-22 10:40AM
Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW)
(ACCESSWIRE)
10:07AM
Sunshine Biopharma, Inc. Announces Closing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
(GlobeNewswire)
Feb-15-22 09:00AM
Sunshine Biopharma, Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
(GlobeNewswire) -77.24%
Dec-22-21 08:52AM
Sunshine Biopharma Announces $1,361,000 in Debt Reduction
(GlobeNewswire)
Nov-03-21 12:35PM
Sunshine Biopharma Expands Board of Directors
(GlobeNewswire)
Oct-06-21 08:00AM
Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
(GlobeNewswire)
Aug-12-21 09:00AM
Sunshine Biopharmas Coronavirus Treatment Anticipated to be Effective Against Delta and the Other Variants of Concern
(GlobeNewswire) +32.76%
Jul-27-21 09:00AM
Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
(GlobeNewswire)
Jul-20-21 09:00AM
Sunshine Biopharma Receives $0.9 Million in Additional Funding From RB Capital
(GlobeNewswire)
Jul-08-21 09:00AM
Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer
(GlobeNewswire)
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.

Institutional Ownership

Connective Capital Management, LLC0.57%
MORGAN STANLEY0.38%
UBS Group AG0.04%
SBI Securities Co., Ltd.0.04%
NATIONAL BANK OF CANADA /FI/0.00%
BANK OF AMERICA CORP /DE/0.00%
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO0.00%
Farther Finance Advisors, LLC0.00%
TD Waterhouse Canada Inc.0.00%
Federation des caisses Desjardins du Quebec0.00%
Income Statement • Balance Sheet • Cash Flow

Data

Timeframe

PeriodTTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period End Date—12/31/202412/31/202312/31/202212/31/202112/31/202012/31/201912/31/2018
Period Length12 Months12 Months12 Months

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.

Learn more
Total Revenue
34.8734.8724.09
Cost of Goods Sold Incl. D&A
24.4324.4315.90
Gross Profit
10.4510.458.19
Selling, General and Administrative Excl. Other
15.8215.8712.69
Research and Development
0.930.931.86
Other Operating Expense
0.390.390.29
Operating Income
-5.76-5.81-4.79
Interest Expense
—0.010.14
Unusual Expense
0.000.000.00
Net Income Before Taxes
-5.37-5.37-4.11
Income Taxes
-0.23-0.230.40
Consolidated Net Income
-5.13-5.13-4.51
Net Income From Continuing Operations
-5.13-5.13-4.51
Net Income
-5.13-5.13-4.51
EPS (Recurring)
-1.99-7.32-370.38
EPS (Basic, Before Extraordinaries)
-51.76-7.32-370.38
EPS (Diluted)
-51.76-7.32-370.38
EBITDA
-5.54-5.59-4.64
Price To Earnings Ratio
-0.03-0.03-0.02
Price To Sales Ratio
0.220.060.27
Gross Margin
29.9529.9533.99
Operating Margin
-16.52-16.67-19.86
Net Margin
-14.72-14.72-18.70
Shares Outstanding
2.582.580.01
Market Capitalization
4.254.255.62
values in Millions, USD
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.